News
The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback